Previous 10 | Next 10 |
home / stock / mycof / mycof news
DENVER, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns Ho...
Groundbreaking Progress in Clinical Trial and Drug Discovery Programs Enhanced Technology Offering with Mindleap 2.0, its Digital Health Platform to Support the Adoption of Psychedelics into Mental Health and Inner Wellness DENVER, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mydecin...
The following slide deck was published by Mydecine Innovations Group Inc. in conjunction with this event. For further details see: Mydecine Innovations (MYCOF) Investor Presentation - Slideshow
DENVER, July 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – July 21, 2021 – The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psiloc...
Mydecine Innovations (MYCOF) has filed a new patent for MDMA-like compounds further expanding its robust portfolio of novel compounds.The patent will allow Mydecine to scale its coverage in drug development research and FDA-approval progress for novel therapeutics.With the file...
DENVER, July 21, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – July 13, 2021 – Telehealth services boomed during 2020, as patients stuck at home required safe access to vital services, and are expected to continue post-pandemic. Before the public he...
The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Co...
The company is developing molecules based on psilocybin to treat PTSD and also has an app for psychedelic after-care remote therapy. Mydecine is the first company in the world to complete an international legal export of dried magic mushrooms. The future for psychedelic-assisted t...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Vancouver, British Columbia, July 5, 2024— TheNewswire – Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to confirm that further to its news release dated June 13, 2024, ...
(TheNewswire) Vancouver, British Columbia, May 31, 2024 - TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2...
(TheNewswire) Vancouver, British Columbia – TheNewswire - May 16, 2024— Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order gr...